• Explore /
  • Poster
  • / KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma (BCL).

KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma (BCL).

Abstract Video & Slides Poster

Authors

null

Loretta J. Nastoupil

The University of Texas MD Anderson Cancer Center, Houston, TX

Loretta J. Nastoupil , Saurabh Dahiya , David Bernard Miklos , Patrick Michael Reagan , Matthew Ulrickson , A. Scott Jung , Ioana Kloos , Jinghui Dong , Justin Chou , Jodi Murakami , Katherine Rodriguez , Myrna Nahas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL

Clinical Trial Registration Number

NCT04989803

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS7579)

DOI

10.1200/JCO.2022.40.16_suppl.TPS7579

Abstract #

TPS7579

Poster Bd #

231a

Abstract Disclosures

Similar Posters

First Author: Frederick L. Locke

First Author: Hui Liu

First Author: Ian Flinn

First Author: Lei Xiao